Baxter International Inc vs Tripadvisor Inc Common Stock — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Tripadvisor Inc Common Stock trades at $14.42 (market cap $1.63B). The key difference: Baxter International Inc is far larger — about 6.9× Tripadvisor Inc Common Stock's market cap, and Baxter International Inc pays a 0.92% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| BAX | TRIP | |
|---|---|---|
Market Cap | $11.26B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $19.14 |
52-Week Low | $15.80 | $9.24 |
Enterprise Value | $18.93B | $1.75B |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Tripadvisor (TRIP) trades at $14.40, up 3.0% today, with technical indicators showing bullish momentum. The company reported mixed Q2 2026 earnings, missing expectations in two of the last three quarters. Recent news highlights the $700 million sale of TheFork to American Express, which may provide capital flexibility. Revenue grew to $1.89 billion in 2025, though net margins remain thin at 0.99%. Analyst consensus is mixed with 60.7% hold ratings and a $13.87 price target slightly below current levels.
The outlook is cautious due to competitive pressures and inconsistent earnings, but the stock shows technical strength. Opportunities include potential benefits from the TheFork sale and travel sector recovery. Key risks are macroeconomic headwinds and execution challenges in core segments. Investors should weigh solid cash flow against high P/E valuation and analyst skepticism for near-term performance.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →